DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

PEG-Intron (Peginterferon Alfa-2B) - Platelet Count Decreased - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Platelet Count Decreased (84)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to PEG-Intron (Peginterferon Alfa-2B) where reactions include platelet count decreased. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 84   Next >>

Possible PEG-Intron side effects in

Reported by a consumer/non-health professional from Japan on 2012-08-27

Patient:

Reactions: Platelet Count Decreased

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 100 microgram, qw
    Start date: 2012-05-02
    End date: 2012-05-02

PEG-Intron
    Dosage: 40 microgram, qw
    Start date: 2012-06-06
    End date: 2012-06-20

PEG-Intron
    Dosage: 50 microgram, qw
    Start date: 2012-04-18
    End date: 2012-04-18

PEG-Intron
    Dosage: 1.5 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-04-11
    End date: 2012-04-11

PEG-Intron
    Dosage: 30 microgram,
    Start date: 2012-06-27
    End date: 2012-06-27

PEG-Intron
    Dosage: 75 microgram, qw
    Start date: 2012-04-25
    End date: 2012-04-25

PEG-Intron
    Dosage: 50 microgram, qw
    Start date: 2012-05-09
    End date: 2012-05-30

PEG-Intron
    Dosage: 40 microgram, unk
    Start date: 2012-07-04

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-11

Telavic
    Dosage: 1.5 g, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-11
    End date: 2012-04-14

Telavic
    Dosage: 1.5 g, qd
    Administration route: Oral
    End date: 2012-06-27

Telavic
    Dosage: unk
    Administration route: Oral
    Start date: 2012-04-17

Other drugs received by patient: Glycyron; Talion (Bepotastine Besylate); Loxonin; Loxonin; Urso 250; NEO-Minophagen C; Motilium



Possible PEG-Intron side effects in

Reported by a consumer/non-health professional from Japan on 2012-08-27

Patient:

Reactions: White Blood Cell Count Decreased, Renal Impairment, Anaemia, Platelet Count Decreased, Decreased Appetite

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 mcg /kg/week
    Indication: Hepatitis C
    Start date: 2012-04-13
    End date: 2012-04-25

PEG-Intron
    Dosage: 1.0 mcg /kg/week
    Start date: 2012-06-26

PEG-Intron
    Dosage: 1.0 mcg /kg/week
    Start date: 2012-04-26
    End date: 2012-06-06

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-13
    End date: 2012-06-06

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-06-26

Telavic
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-13
    End date: 2012-06-07

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Start date: 2012-06-26
    End date: 2012-07-24

Other drugs received by patient: Motilium; Lorfenamin; Motilium; L Cartin; Rikkunshi-TO; Epadel



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-24

Patient:

Reactions: Haemoglobin Decreased, Platelet Count Decreased

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.3 microgram per kilogram, qw
    Start date: 2012-06-01

PEG-Intron
    Dosage: 1.7 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-04-27
    End date: 2012-05-25

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-06-29

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-27
    End date: 2012-05-17

Rebetol
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-06-01
    End date: 2012-06-07

Rebetol
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-06-22
    End date: 2012-06-28

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-05-18
    End date: 2012-05-31

Telavic
    Dosage: 1000 mg, qd
    Administration route: Oral
    Start date: 2012-06-01
    End date: 2012-06-07

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-27
    End date: 2012-05-31

Telavic
    Dosage: 1000 mg, qd
    Administration route: Oral
    Start date: 2012-06-22
    End date: 2012-07-18



Possible PEG-Intron side effects in 67 year old female

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-24

Patient: 67 year old female

Reactions: Nausea, Anaemia, Platelet Count Decreased, Blood Creatinine Increased, Hyperuricaemia, Decreased Appetite

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 0.94 a?g/kg, unk
    Start date: 2012-04-06
    End date: 2012-04-26

PEG-Intron
    Dosage: 1.3 a?g/kg, unk
    Start date: 2012-03-30

PEG-Intron
    Dosage: 1.13 a?g/kg, unk
    Start date: 2012-04-27
    End date: 2012-05-10

PEG-Intron
    Dosage: 1.3 a?g/kg, unk
    Start date: 2012-05-11
    End date: 2012-08-02

PEG-Intron
    Dosage: 1.5 a?g/kg, unk
    Indication: Hepatitis C
    Start date: 2012-02-17
    End date: 2012-03-29

PEG-Intron
    Start date: 2012-05-11

Ribavirin
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-03-16
    End date: 2012-04-19

Ribavirin
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-02-24
    End date: 2012-03-15

Ribavirin
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-04-20
    End date: 2012-08-02

Ribavirin
    Dosage: 600 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-17
    End date: 2012-02-23

VX-950
    Dosage: 750 mg, qd
    Administration route: Oral
    Start date: 2012-03-23
    End date: 2012-04-13

VX-950
    Dosage: 1500 mg, qd
    Administration route: Oral
    Start date: 2012-02-24
    End date: 2012-03-22

VX-950
    Dosage: 2250 mg, qd
    Indication: Hepatitis C
    Start date: 2012-02-17
    End date: 2012-02-23

Other drugs received by patient: Diovan; Urso / 00465701 /; Innolet; Amlodipine



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-23

Patient:

Reactions: Haemoglobin Decreased, Platelet Count Decreased

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-05-25
    End date: 2012-05-31

PEG-Intron
    Dosage: 0.75 microgram per kilogram, qw
    Start date: 2012-06-01

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Start date: 2012-06-22

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-25
    End date: 2012-06-21

Rebetol
    Dosage: unk

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-25



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-23

Patient:

Reactions: Pneumonia, Platelet Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 microgram per kilogram
    Start date: 2012-03-06
    End date: 2012-03-13

PEG-Intron
    Dosage: 0.75 microgram per kilogram, qw
    Start date: 2012-05-15

PEG-Intron
    Dosage: 0.75 microgram per kilogram, qw
    Start date: 2012-03-20
    End date: 2012-05-01

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Start date: 2012-05-15

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-06
    End date: 2012-05-07

Telaprevir
    Dosage: 2250 mg, qd
    Administration route: Oral
    Start date: 2012-05-15
    End date: 2012-06-05

Telaprevir
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-06
    End date: 2012-05-07

Other drugs received by patient: Betamethasone Sodium Phosphate; [therapy Unspecified]; Allegra; Allopurinol; Rabeprazole Sodium; Atarax; Meropenem



Possible PEG-Intron side effects in

Reported by a consumer/non-health professional from Japan on 2012-08-23

Patient:

Reactions: Anaemia, Platelet Count Decreased

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-06-06

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-06
    End date: 2012-06-25

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-06-26

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-06

Other drugs received by patient: Ferotym; Claritin Reditabs; Livalo; Epadel S



Possible PEG-Intron side effects in

Reported by a consumer/non-health professional from Japan on 2012-08-23

Patient:

Reactions: Platelet Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-05-30
    End date: 2012-06-06

PEG-Intron
    Dosage: 1.5 microgram, per week
    Start date: 2012-06-13

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Start date: 2012-06-13
    End date: 2012-06-27

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-07-04
    End date: 2012-07-11

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-30
    End date: 2012-06-06

Rebetol
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-07-11

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Start date: 2012-06-27
    End date: 2012-07-04

Telavic
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-30
    End date: 2012-06-06

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Start date: 2012-06-13

Other drugs received by patient: Allopurinol; Urso 250; Loxonin; Mucosta



Possible PEG-Intron side effects in

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-22

Patient:

Reactions: Confusional State, Affect Lability, Completed Suicide, Platelet Count Decreased

Adverse event resulted in: death

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 80 microgram, qw
    Start date: 2012-05-29
    End date: 2012-06-05

PEG-Intron
    Dosage: 120 microgram, qw
    Indication: Hepatitis C
    Start date: 2012-05-23
    End date: 2012-05-23

Rebetol
    Dosage: 1000 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-23
    End date: 2012-06-01



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-22

Patient:

Reactions: Hepatic Encephalopathy, Dehydration, Hyperammonaemia, Platelet Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.23mcg/kg/week
    Start date: 2012-03-24

PEG-Intron
    Dosage: 1.48mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-01-21
    End date: 2012-02-17

PEG-Intron
    Dosage: 1.10mcg/kg/week
    Start date: 2012-03-03
    End date: 2012-03-23

PEG-Intron
    Dosage: 1.38mcg/kg/week
    Start date: 2012-02-18
    End date: 2012-03-02

Rebetol
    Administration route: Oral
    Start date: 2012-03-11
    End date: 2012-04-14

Rebetol
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-21
    End date: 2012-02-03

Rebetol
    Administration route: Oral
    Start date: 2012-04-15
    End date: 2012-05-12

Rebetol
    Administration route: Oral
    Start date: 2012-05-13

Rebetol
    Administration route: Oral
    Start date: 2012-02-04
    End date: 2012-03-10

Telavic
    Administration route: Oral
    Start date: 2012-03-01
    End date: 2012-04-14

Telavic
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-21
    End date: 2012-02-29

Other drugs received by patient: Nexium; Xyzal



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-15

Patient:

Reactions: Anaemia, Platelet Count Decreased

Drug(s) suspected as cause:
Incivek
    Dosage: 1500 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-05

PEG-Intron
    Dosage: 1.0 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-06-05
    End date: 2012-06-18

Rebetol
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-06-25

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-05
    End date: 2012-06-24

Other drugs received by patient: Ferotym; Epadel S; Claritin Reditabs; Rabeprazole Sodium; Maglax (Magnesium Oxide); PEG-Intron; PEG-Intron



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-14

Patient:

Reactions: Platelet Count Decreased, Rash

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.7mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-06-12
    End date: 2012-06-18

PEG-Intron
    Dosage: 1.27mcg/kg/week
    Start date: 2012-06-25

Rebetol
    Administration route: Oral
    Start date: 2012-06-25

Rebetol
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-12
    End date: 2012-06-18

Telavic
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-12
    End date: 2012-06-18

Telavic
    Administration route: Oral
    Start date: 2012-06-25



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-14

Patient:

Reactions: Haemoglobin Decreased, Anaemia, Platelet Count Decreased

Drug(s) suspected as cause:
Antiviral (Unspecified)
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-09
    End date: 2012-04-26

Antiviral (Unspecified)
    Dosage: 750 mg, qd
    Administration route: Oral
    Start date: 2012-04-27
    End date: 2012-05-01

Antiviral (Unspecified)
    Dosage: 750 mg, qd
    Administration route: Oral
    Start date: 2012-05-25

PEG-Intron
    Dosage: 1.5mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-03-09
    End date: 2012-04-20

PEG-Intron
    Dosage: 0.75mcg/kg/week
    Start date: 2012-06-01

PEG-Intron
    Dosage: 0.6mcg/kg/week
    Start date: 2012-04-27
    End date: 2012-04-27

PEG-Intron
    Dosage: 0.6mcg/kg/week
    Start date: 2012-05-18
    End date: 2012-05-25

Rebetol
    Dosage: 1000 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-09
    End date: 2012-04-12

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Start date: 2012-04-13
    End date: 2012-04-26

Telavic
    Administration route: Oral
    Start date: 2012-05-25

Telavic
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-09
    End date: 2012-04-26

Telavic
    Administration route: Oral
    Start date: 2012-04-27
    End date: 2012-05-01

Other drugs received by patient: Miya BM; Taipemin; Allopurinol; Allopurinol; Lanizac; Valsartan and Hydrochlorothiazide; Urso 250; Sodium Ferrous Citrate; Ranitidine Hydrochloride; Valsartan and Hydrochlorothiazide; Bezafibrate; Bezafibrate; Allopurinol; Allopurinol



Possible PEG-Intron side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-14

Patient:

Reactions: Contusion, Hypotension, Dizziness, Platelet Count Decreased, Loss of Consciousness

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-05-17

Rebetol
    Dosage: 2 df, bid
    Indication: Hepatitis C
    Start date: 2012-05-17
    End date: 2012-07-01

Rebetol
    Dosage: 1 df, bid
    Start date: 2012-07-01

Other drugs received by patient: Nifedipine; Coreg; Temazepam; Oxycodone; Amitriptyline HCL; Fosamax; Lisinopril; Aspirin



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-14

Patient:

Reactions: Haemoglobin Decreased, Platelet Count Decreased

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.2mcg/kg/week
    Start date: 2012-06-04

PEG-Intron
    Dosage: 1.5mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-01-17
    End date: 2012-02-20

PEG-Intron
    Dosage: 1.3mcg/kg/week
    Start date: 2012-02-27
    End date: 2012-02-27

PEG-Intron
    Dosage: 0.9mcg/kg/week
    Start date: 2012-04-09
    End date: 2012-05-28

PEG-Intron
    Dosage: 0.9mcg/kg/week
    Start date: 2012-03-05
    End date: 2012-03-05

PEG-Intron
    Dosage: 1.3mcg/kg/week
    Start date: 2012-03-12
    End date: 2012-04-02

Rebetol
    Administration route: Oral
    Start date: 2012-07-09

Rebetol
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-17
    End date: 2012-02-19

Rebetol
    Administration route: Oral
    Start date: 2012-03-05
    End date: 2012-04-08

Rebetol
    Administration route: Oral
    Start date: 2012-04-09
    End date: 2012-04-22

Rebetol
    Administration route: Oral
    Start date: 2012-06-18
    End date: 2012-07-08

Rebetol
    Administration route: Oral
    Start date: 2012-02-20
    End date: 2012-03-04

Rebetol
    Administration route: Oral
    Start date: 2012-04-23
    End date: 2012-06-17

Telavic
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-17
    End date: 2012-04-09

Other drugs received by patient: Famotidine



Possible PEG-Intron side effects in

Reported by a pharmacist from United States on 2012-08-10

Patient:

Reactions: Fatigue, Anaemia, Platelet Count Decreased

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 120 microgram, qw

Rebetol
    Dosage: 200 mg, unk

Other drugs received by patient: MK-0521



Possible PEG-Intron side effects in

Reported by a individual with unspecified qualification from Japan on 2012-08-10

Patient:

Reactions: Renal Disorder, Amylase Increased, Anaemia, Platelet Count Decreased, Neutrophil Count Decreased, Hyperuricaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Antiviral (Unspecified)
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-22
    End date: 2012-02-24

Antiviral (Unspecified)
    Dosage: 1500 mg, qd
    Administration route: Oral
    Start date: 2012-02-25

PEG-Intron
    Dosage: unk microgram per kilogram, unk
    Indication: Hepatitis C
    Start date: 2012-02-22

Peginterferon Alfa-2B
    Dosage: 0.75 ?g/kg, qw
    Indication: Hepatitis C
    Start date: 2012-02-22

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-03-02
    End date: 2012-04-11

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-22
    End date: 2012-03-01

Rebetol
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-04-12

Telavic
    Dosage: 1500 mg, once
    Administration route: Oral
    Start date: 2012-02-25

Telavic
    Dosage: 2250 mg, once
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-22
    End date: 2012-02-24

Other drugs received by patient: Olmesartan Medoxomil; Claritin; Olmesartan Medoxomil; Allopurinol; Acetaminophen; Allegra; Celestamine TAB; Berizym (Aspergillus Oryzae Extract (+) Cellulase (+) Lipase (+) Pancr; Aspergillus Oryzae Extract (+) Cellulase (+) Lipase (+) Pancreatin; Myser (Cycloserine)



Possible PEG-Intron side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-10

Patient:

Reactions: Basedow's Disease, Weight Decreased, Pruritus, Diabetes Mellitus, Rectal Haemorrhage, Blood Count Abnormal, Appetite Disorder, RED Blood Cell Count Decreased, Anorectal Discomfort, Oedema Peripheral, White Blood Cell Count Decreased, Faeces Hard, Dysgeusia, Mental Impairment, Diarrhoea, Disease Recurrence, Alopecia, Platelet Count Decreased, Asthenia

Drug(s) suspected as cause:
PEG-Intron
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2002-01-04

Pegasys
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2005-04-01
    End date: 2006-03-03

Pegasys
    Dosage: unk
    Start date: 2012-03-22

Rebetol
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2002-01-04

Rebetol
    Dosage: 3 df, qd
    Start date: 2012-03-22

Rebetol
    Dosage: unk
    Start date: 2005-04-01
    End date: 2006-03-03

Victrelis
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-04-19



Possible PEG-Intron side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-10

Patient:

Reactions: Platelet Count Decreased, Ammonia Increased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-05-04

Rebetol
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-05-04

Victrelis
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-06-02



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-10

Patient:

Reactions: Haemoglobin Decreased, Platelet Count Decreased

Drug(s) suspected as cause:
Antiviral (Unspecified)
    Dosage: 1500 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-21

PEG-Intron
    Dosage: 30mcg/kg/week
    Start date: 2012-04-11

PEG-Intron
    Dosage: 0.89mcg/kg/week
    End date: 2012-06-05

PEG-Intron
    Dosage: 40mcg/kg/week
    Start date: 2012-04-25

PEG-Intron
    Dosage: 1.33mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-03-21

PEG-Intron
    Dosage: 0mcg/kg/week
    Start date: 2012-06-06

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-21
    End date: 2012-03-27

Rebetol
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-03-28

Rebetol
    Administration route: Oral
    Start date: 2012-03-28
    End date: 2012-06-05

Rebetol
    Administration route: Oral
    Start date: 2012-06-06

Telavic
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-21

Telavic
    Administration route: Oral
    Start date: 2012-06-06

Telavic
    Administration route: Oral
    Start date: 2012-05-30
    End date: 2012-06-05

Other drugs received by patient: Gasmotin; Allegra; Antebate; [therapy Unspecified]; Herbs (Unspecified)



Possible PEG-Intron side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-10

Patient:

Reactions: Back Pain, Arthralgia, Alopecia, Anaemia, Platelet Count Decreased, Cerebrovascular Accident, Eye Disorder

Drug(s) suspected as cause:
PEG-Intron
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-01-01
    End date: 2012-07-28

Rebetol
    Dosage: unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-01
    End date: 2012-07-28

Victrelis
    Dosage: unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-29
    End date: 2012-07-28



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-10

Patient:

Reactions: Haemoglobin Decreased, Gout, Platelet Count Decreased, Hyperuricaemia

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 0.5mcg/kg/week
    Start date: 2012-03-30

PEG-Intron
    Dosage: 1.0mcg/kg/week
    Start date: 2012-03-16
    End date: 2012-03-29

PEG-Intron
    Dosage: 0.45mcg/kg/week
    Start date: 2012-05-11
    End date: 2012-05-18

PEG-Intron
    Dosage: 1.1mcg/kg/week
    Start date: 2012-03-02
    End date: 2012-03-15

PEG-Intron
    Dosage: 0.45mcg/kg/week
    Start date: 2012-03-30
    End date: 2012-04-06

PEG-Intron
    Dosage: 0.75mcg/kg/week
    Start date: 2012-04-20
    End date: 2012-05-04

PEG-Intron
    Dosage: 1.5mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-02-16
    End date: 2012-03-01

PEG-Intron
    Dosage: 0.6mcg/kg/week
    Start date: 2012-04-13
    End date: 2012-04-13

Rebetol
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-16
    End date: 2012-03-15

Rebetol
    Administration route: Oral
    Start date: 2012-05-12

Rebetol
    Administration route: Oral
    Start date: 2012-03-16
    End date: 2012-03-22

Rebetol
    Administration route: Oral
    Start date: 2012-03-23
    End date: 2012-03-30

Rebetol
    Administration route: Oral
    Start date: 2012-04-06
    End date: 2012-05-11

Telavic
    Administration route: Oral
    Start date: 2012-03-23
    End date: 2012-03-30

Telavic
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-16
    End date: 2012-03-22

Telavic
    Administration route: Oral
    Start date: 2012-04-06
    End date: 2012-05-10

Other drugs received by patient: Revolade; Confatanin; Revolade



Possible PEG-Intron side effects in

Reported by a consumer/non-health professional from United States on 2012-08-07

Patient:

Reactions: White Blood Cell Count Decreased, Pruritus, Impaired Healing, Tooth Abscess, Skin Lesion, Tooth Extraction, Platelet Count Decreased, Memory Impairment

Drug(s) suspected as cause:
PEG-Intron
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-06-04

Rebetol
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-06-04

Victrelis
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-07-02



Possible PEG-Intron side effects in

Reported by a individual with unspecified qualification from Japan on 2012-08-02

Patient:

Reactions: Drug Eruption, Anaemia, Platelet Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Antiviral (Unspecified)
    Dosage: 1000 mg, qd
    Administration route: Oral
    Start date: 2012-05-25

Antiviral (Unspecified)
    Dosage: 1500 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-17
    End date: 2012-05-24

PEG-Intron
    Dosage: 1.5mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-04-17

Rebetol
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-05-11

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-17
    End date: 2012-05-10

Telavic
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-17
    End date: 2012-05-24

Telavic
    Administration route: Oral
    Start date: 2012-05-25

Other drugs received by patient: Livalo; Livalo; Rabeprazole Sodium; Norvasc; Sodium Ferrous Citrate; Ferotym; Claritin Reditabs; Norvasc; Epadel; Rabeprazole Sodium; Epadel S; Tamsulosin Hydrochloride; Tamsulosin Hydrochloride; Claritin Reditabs



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-01

Patient:

Reactions: White Blood Cell Count Decreased, Haemoglobin Decreased, RED Blood Cell Count Decreased, Blood Albumin Decreased, Platelet Count Decreased, Protein Total Decreased, Neutrophil Count Decreased

Drug(s) suspected as cause:
Interferon Beta NOS
    Indication: Hepatitis C
    Start date: 2010-08-16
    End date: 2010-08-18

Interferon Beta NOS
    Start date: 2010-08-23
    End date: 2010-09-06

Interferon Beta NOS
    Start date: 2010-09-21
    End date: 2010-10-12

Interferon Beta NOS
    Start date: 2010-08-19
    End date: 2010-08-21

Interferon Beta NOS
    Start date: 2010-09-07
    End date: 2010-09-18

PEG-Intron
    Dosage: unk unk, qw
    Indication: Hepatitis C
    Start date: 2010-10-15
    End date: 2011-02-04

Rebetol
    Administration route: Oral
    Start date: 2010-10-01
    End date: 2010-10-14

Rebetol
    Dosage: 400 mg in the morning, 200 mg in the evening
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2010-08-16
    End date: 2010-09-30

Rebetol
    Administration route: Oral
    Start date: 2010-10-15

Other drugs received by patient: Loxonin



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-01

Patient:

Reactions: Malaise, Platelet Count Decreased

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-04-03
    End date: 2012-06-05

Rebetol
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-03
    End date: 2012-06-05

Telavic
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-03
    End date: 2012-06-05

Other drugs received by patient: Antebate; Prednisolone; [therapy Unspecified]



Possible PEG-Intron side effects in

Reported by a physician from United States on 2012-08-01

Patient:

Reactions: White Blood Cell Count Decreased, Pruritus, Pain, Platelet Count Decreased, Rash, Blister

Drug(s) suspected as cause:
PEG-Intron
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2011-08-19

Rebetol
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2011-08-19

Other drugs received by patient: Telaprevir



Possible PEG-Intron side effects in 75 year old male

Reported by a individual with unspecified qualification from Japan on 2012-07-31

Patient: 75 year old male

Reactions: Rhabdomyolysis, Henoch-Schonlein Purpura, Platelet Count Decreased, Oropharyngeal Pain, Pyrexia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: dosage is uncertain.
    Indication: Hepatitis C
    Start date: 2006-12-01

Rebetol
    Dosage: dosage is uncertain.
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2006-12-01



Possible PEG-Intron side effects in

Reported by a physician from Austria on 2012-07-30

Patient:

Reactions: Agranulocytosis, Anaemia, Platelet Count Decreased, Leukopenia

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 100 microgram, unk
    Indication: Hepatitis C
    Start date: 2012-03-21
    End date: 2012-06-10

Rebetol
    Dosage: unk
    Indication: Hepatitis C

Victrelis
    Dosage: 800 mg, tid
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-21
    End date: 2012-06-10



Possible PEG-Intron side effects in

Reported by a consumer/non-health professional from Brazil on 2012-07-26

Patient:

Reactions: White Blood Cell Count Decreased, Weight Decreased, Dysentery, Diarrhoea, Oedema Peripheral, Abdominal Distension, Platelet Count Decreased, Neutrophil Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 80 unk, unk
    Start date: 2012-06-16

PEG-Intron
    Dosage: 120 microgram, unk
    Indication: Hepatitis C
    Start date: 2012-05-26
    End date: 2012-06-15

Ribavirin
    Dosage: 2 tablets, bid
    Administration route: Oral
    Start date: 2002-01-01
    End date: 2002-01-01

Ribavirin
    Dosage: 2 tablets, qam
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-01

Ribavirin
    Dosage: 1 tablet, qpm
    Administration route: Oral
    Start date: 2012-01-01

Victrelis
    Dosage: unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-16

Other drugs received by patient: Filgrastim; Epoetin



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017